Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized Placebo Controlled Trial

Study Questions:

What is the effect of interleukin (IL)-1β inhibition on surrogate markers of inflammation in diabetic patients at high risk for cardiovascular disease (CVD)?